Revealed Gap in Antithrombotic Therapy for Atrial Fibrillation in Acute Decompensated Heart Failure Patients: A Report from the Attend Registry

Takehiko Keida, Kuniya Asai, Katsuya Kajimoto, Yasushi Sakata, Masayuki Mizuno, Dai Yumino, Yuichiro Minami, Toshiyuki Aokage, Koji Murai, Ryo Munakata, Naoki Sato

Research output: Contribution to journalArticle

Abstract

Objective: CHADS2 score can quantify risk of stroke for patients who have atrial fibrillation (AF) and may aid in selection of antithrombotic therapy. The aim of this study was to investigate the relationship between CHADS2 score and antithrombotic therapy in acute decompensated heart failure (ADHF) patients with AF. Methods: The ATTEND registry in an ongoing prospective observational multicenter cohort study of patients hospitalized for ADHF in Japan. We evaluated 1027 ADHF patients with AF admitted to 48 hospitals (mean age 74.8±11.5year old, male 56.2%, LVEF 49.1 ±16.7%). We classified them in 6 groups according to CHADS2 score of 1 to 6 (score1:n=133, 2:n=279, 3:n=366, 4:n=132, 5:n=86, 6:n=31). Antithrombotic therapy was compared according to CHADS2 score. Results: As the CHADS2 score increased, the ratio of warfarin use was decreased (total:77.0%, score1:85.7%, 2:83.5%, 3:73.2%, 4:78.0%, 5:60.5%, 6:67.7%, p<0.001). On the other hand, the ratio of aspirin use was increased (total:35.3%, score1:17.3%, 2:27.6%, 3:41.3%, 4:43.2%, 5:43.0%, 6:58.1%, p<0.001). Conclusion: In ADHF patients with AF, the underuse of warfarin were observed at high CHADS2 score.

Original languageEnglish
JournalJournal of Arrhythmia
Volume27
DOIs
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Atrial Fibrillation
Registries
Heart Failure
Warfarin
Therapeutics
Aspirin
Multicenter Studies
Japan
Cohort Studies
Stroke

Keywords

  • AF
  • CHADS2 score
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Revealed Gap in Antithrombotic Therapy for Atrial Fibrillation in Acute Decompensated Heart Failure Patients : A Report from the Attend Registry. / Keida, Takehiko; Asai, Kuniya; Kajimoto, Katsuya; Sakata, Yasushi; Mizuno, Masayuki; Yumino, Dai; Minami, Yuichiro; Aokage, Toshiyuki; Murai, Koji; Munakata, Ryo; Sato, Naoki.

In: Journal of Arrhythmia, Vol. 27, 01.01.2011.

Research output: Contribution to journalArticle

Keida, Takehiko ; Asai, Kuniya ; Kajimoto, Katsuya ; Sakata, Yasushi ; Mizuno, Masayuki ; Yumino, Dai ; Minami, Yuichiro ; Aokage, Toshiyuki ; Murai, Koji ; Munakata, Ryo ; Sato, Naoki. / Revealed Gap in Antithrombotic Therapy for Atrial Fibrillation in Acute Decompensated Heart Failure Patients : A Report from the Attend Registry. In: Journal of Arrhythmia. 2011 ; Vol. 27.
@article{893b650752364c82b61c97076e63a43c,
title = "Revealed Gap in Antithrombotic Therapy for Atrial Fibrillation in Acute Decompensated Heart Failure Patients: A Report from the Attend Registry",
abstract = "Objective: CHADS2 score can quantify risk of stroke for patients who have atrial fibrillation (AF) and may aid in selection of antithrombotic therapy. The aim of this study was to investigate the relationship between CHADS2 score and antithrombotic therapy in acute decompensated heart failure (ADHF) patients with AF. Methods: The ATTEND registry in an ongoing prospective observational multicenter cohort study of patients hospitalized for ADHF in Japan. We evaluated 1027 ADHF patients with AF admitted to 48 hospitals (mean age 74.8±11.5year old, male 56.2{\%}, LVEF 49.1 ±16.7{\%}). We classified them in 6 groups according to CHADS2 score of 1 to 6 (score1:n=133, 2:n=279, 3:n=366, 4:n=132, 5:n=86, 6:n=31). Antithrombotic therapy was compared according to CHADS2 score. Results: As the CHADS2 score increased, the ratio of warfarin use was decreased (total:77.0{\%}, score1:85.7{\%}, 2:83.5{\%}, 3:73.2{\%}, 4:78.0{\%}, 5:60.5{\%}, 6:67.7{\%}, p<0.001). On the other hand, the ratio of aspirin use was increased (total:35.3{\%}, score1:17.3{\%}, 2:27.6{\%}, 3:41.3{\%}, 4:43.2{\%}, 5:43.0{\%}, 6:58.1{\%}, p<0.001). Conclusion: In ADHF patients with AF, the underuse of warfarin were observed at high CHADS2 score.",
keywords = "AF, CHADS2 score, warfarin",
author = "Takehiko Keida and Kuniya Asai and Katsuya Kajimoto and Yasushi Sakata and Masayuki Mizuno and Dai Yumino and Yuichiro Minami and Toshiyuki Aokage and Koji Murai and Ryo Munakata and Naoki Sato",
year = "2011",
month = "1",
day = "1",
doi = "10.4020/jhrs.27.OP49_3",
language = "English",
volume = "27",
journal = "Journal of Arrhythmia",
issn = "1880-4276",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Revealed Gap in Antithrombotic Therapy for Atrial Fibrillation in Acute Decompensated Heart Failure Patients

T2 - A Report from the Attend Registry

AU - Keida, Takehiko

AU - Asai, Kuniya

AU - Kajimoto, Katsuya

AU - Sakata, Yasushi

AU - Mizuno, Masayuki

AU - Yumino, Dai

AU - Minami, Yuichiro

AU - Aokage, Toshiyuki

AU - Murai, Koji

AU - Munakata, Ryo

AU - Sato, Naoki

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: CHADS2 score can quantify risk of stroke for patients who have atrial fibrillation (AF) and may aid in selection of antithrombotic therapy. The aim of this study was to investigate the relationship between CHADS2 score and antithrombotic therapy in acute decompensated heart failure (ADHF) patients with AF. Methods: The ATTEND registry in an ongoing prospective observational multicenter cohort study of patients hospitalized for ADHF in Japan. We evaluated 1027 ADHF patients with AF admitted to 48 hospitals (mean age 74.8±11.5year old, male 56.2%, LVEF 49.1 ±16.7%). We classified them in 6 groups according to CHADS2 score of 1 to 6 (score1:n=133, 2:n=279, 3:n=366, 4:n=132, 5:n=86, 6:n=31). Antithrombotic therapy was compared according to CHADS2 score. Results: As the CHADS2 score increased, the ratio of warfarin use was decreased (total:77.0%, score1:85.7%, 2:83.5%, 3:73.2%, 4:78.0%, 5:60.5%, 6:67.7%, p<0.001). On the other hand, the ratio of aspirin use was increased (total:35.3%, score1:17.3%, 2:27.6%, 3:41.3%, 4:43.2%, 5:43.0%, 6:58.1%, p<0.001). Conclusion: In ADHF patients with AF, the underuse of warfarin were observed at high CHADS2 score.

AB - Objective: CHADS2 score can quantify risk of stroke for patients who have atrial fibrillation (AF) and may aid in selection of antithrombotic therapy. The aim of this study was to investigate the relationship between CHADS2 score and antithrombotic therapy in acute decompensated heart failure (ADHF) patients with AF. Methods: The ATTEND registry in an ongoing prospective observational multicenter cohort study of patients hospitalized for ADHF in Japan. We evaluated 1027 ADHF patients with AF admitted to 48 hospitals (mean age 74.8±11.5year old, male 56.2%, LVEF 49.1 ±16.7%). We classified them in 6 groups according to CHADS2 score of 1 to 6 (score1:n=133, 2:n=279, 3:n=366, 4:n=132, 5:n=86, 6:n=31). Antithrombotic therapy was compared according to CHADS2 score. Results: As the CHADS2 score increased, the ratio of warfarin use was decreased (total:77.0%, score1:85.7%, 2:83.5%, 3:73.2%, 4:78.0%, 5:60.5%, 6:67.7%, p<0.001). On the other hand, the ratio of aspirin use was increased (total:35.3%, score1:17.3%, 2:27.6%, 3:41.3%, 4:43.2%, 5:43.0%, 6:58.1%, p<0.001). Conclusion: In ADHF patients with AF, the underuse of warfarin were observed at high CHADS2 score.

KW - AF

KW - CHADS2 score

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85009593112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009593112&partnerID=8YFLogxK

U2 - 10.4020/jhrs.27.OP49_3

DO - 10.4020/jhrs.27.OP49_3

M3 - Article

AN - SCOPUS:85009593112

VL - 27

JO - Journal of Arrhythmia

JF - Journal of Arrhythmia

SN - 1880-4276

ER -